Cart
sales@molnova.com
JUN04542
CAS No. 2367004-54-2
JUN04542( CL-092 )
Catalog No. M24079 CAS No. 2367004-54-2
JUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 110 | In Stock |
|
| 10MG | 177 | In Stock |
|
| 25MG | 410 | In Stock |
|
| 50MG | 605 | In Stock |
|
| 100MG | 860 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJUN04542
-
NoteResearch use only, not for human use.
-
Brief DescriptionJUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
-
DescriptionJUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
-
In Vitro——
-
In VivoAnimal Model:Rat Dosage:3 mg/kg (Pharmacokinetic Analysis) Administration:IV Result:Had a T1/2 of 5.4 hours, a CL of 43 mL/hr?kg.
-
SynonymsCL-092
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorAxl|c-Met|KDR|Mer
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2367004-54-2
-
Formula Weight528.53
-
Molecular FormulaC29H25FN4O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lynne Canne Bannen, Minna Bui, Faming Jiang, et al Compounds for the treatment of kinase-dependent disorders;WO 2019148044
molnova catalog
related products
-
PLB-1001
PLB-1001 (Bozitinib, PLB1001, CBI-3103, CBT-101) is a potent, highly selective, ATP-competitive, BBB-permeable MET kinase inhibitor, potently inhibits MET activity by 95.1% at 2 uM.
-
Telisotuzumab
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.
-
JNJ-38877605
JNJ-38877605 is a potent, selective, ATP-competitive inhibitor of catalytic activity c-Met with IC50 of 4 nM.
